演題詳細

一般口演 / Oral Session

一般口演 11 (Oral Session 11) :低悪性度B細胞リンパ腫:治療研究

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
小宅 達郎 (Tatsuo Oyake):1
1:岩手医科大学 血液・腫瘍内科
 
前へ戻る

The efficacy of consolidation radioimmunotherapy in patients with relapsed indolent B cell lymphoma

演題番号 : OS-1-54

氷室 真仁 (Masahito Himuro):1、鎌田 真弓 (Mayumi Kamata):1、木村 淳 (Jun Kimura):2、市川 聡 (Satoshi Ichikawa):2、高川 真徳 (Masanori Takagawa):3、山本 譲司 (Joji Yamamoto):4、木幡 桂 (Katsura Kohata):4、佐々木 治 (Osamu Sasaki):5、遠宮 靖雄 (Yasuo Tohmiya):5、原崎 頼子 (Yoriko Harazaki):5、井根 省二 (Syouji Ine):5、藤井 正実 (Masami Fujii):6、木村 朋文 (Tomofumi Kimura):6、亀岡 吉弘 (Yoshihiro Kameoka):7、野村 順 (Jun Nomura):8、目黒 邦昭 (Kuniaki Meguro):9、石川 泉 (Izumi Ishikawa):10、鈴木 真紀子 (Makiko Suzuki):1、中嶌 真治 (Shinji Nakajima):1、勝岡 優奈 (Yuuna Katsuoka):1、藤原 亨 (Toru Fujiwara):1、沖津 庸子 (Yoko Okitsu):1、福原 規子 (Noriko Fukuhara):1、大西 康 (Yasushi Onishi):1、亀岡 淳一 (Junichi Kameoka):1、石澤 賢一 (Kenichi Ishizawa):1、張替 秀郎 (Hideo Harigae):1

1:Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan、2:Yamagata City Hospital Saisaikan, Yamagata, Japan、3:Japan Red Cross Ishinomaki Hospital, Ishinomaki, Japan、4:Sendai City Hospital, Sendai, Japan、5:Miyagi Cancer Center, Natori, Japan、6:KKR Suihu Hospital, Mito, Japan、7:Department of Hematology, Akita University Hospital, Akita, Japan、8:NTT East Japan Tohoku Hospital, Sendai, Japan、9:Sendai Medical Center, Sendai, Japan、10:Oosaki Municipal Hospital, Oosaki, Japan

 

Background: Combination of chemotherapy and radioimmunotherapy is attractive treatment strategy in patients with relapsed indolent B cell lymphoma. The efficacy of consolidation therapy with yttrium-90(90Y)-ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma in first remission was demonstrated. However, there is not enough evidence of the efficacy of consolidation radioimmunotherapy in patients with relapsed indolent B cell lymphoma. Purpose: The efficacy of short-course immunochemotherapy followed by 90Y-ibritumomab tiuxetan (sequential therapy) was evaluated.Method: Subjects are patients with relapsed indolent B cell lymphoma who received 90Y-ibritumomab tiuxetan therapy from 2004 to 2012 in our hospitals. Patients, previously treated with chemotherapy more than six months before 90Y-ibritumomab tiuxetan therapy (previous group) or sequential therapy (sequential group), were analyzed retrospectively.Results: A total of 33 patients, 13 patients in previous group, and 20 patients in sequential group, age 43 to 75, were analyzed. Median observation period is 24.6month. Median progressin-free-survival (PFS) time was 1.98years in previous group and 1.22years in sequential group, and time-to-next-therapy was 6.38years and 2.34years. For patients who had a complete remission after 90Y-ibritumomab tiuxetan therapy(21 patients), median PFS time was 1.65years in previous group(10 patients), and not reached in sequential group(11 patients). Conclusion: Consolidation radioimmunotherapy may be effective strategy. We need to identify more appropriate patients.

前へ戻る